In this issue of Clinics in Liver Disease, guest editor Robert G. Gish brings his considerable expertise to the topic of Hepatitis B and Hepatitis D. The articles provide state-of-the-art clinical summaries of the advances in Hepatitis B and D, with emphasis on HBV viro-immunology, novel assays, new targets, and tests for HBV and HDV, and more. - Contains 13 relevant, practice-oriented topics including Novel Assays to Solve the Clinical and Scientific Challenges of Chronic Hepatitis B; Maternal-to-Child Transmission of Hepatitis B Virus and Hepatitis Delta Virus; Triple Threat: HDV, HBV, HIV Coinfection; Targeting Hepatitis B Virus DNA Using Designer Gene Editors; and more. - Provides in-depth clinical reviews on Hepatitis B and D, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

In this issue of Clinics in Liver Disease, guest editor Dr. David E. Bernstein brings his considerable expertise to the topic of Autoimmune Hepatitis Including PBC and PSC. The three main immune disorders that involve the liver are AIH, primary biliary cholangitis, and primary sclerosing cholangitis. As these autoimmune diseases can share symptoms, it is important for the hepatologist to have clinical knowledge of each and understand their differences and similarities. This issue addresses these variants and provides the reader with important information relating to pathology, diagnosis, and treatment. Contains 15 relevant, practice-oriented topics including autoimmune hepatitis: epidemiology, subtypes, and presentation; diagnosis of autoimmune hepatitis; treatment of autoimmune hepatitis including transplant; diagnostic tests in primary sclerosing cholangitis: serology, elastography, imaging; post-transplant management and complications of AIH, PBC, and PSC, including disease recurrence; and more. Provides in-depth clinical reviews on autoimmune hepatitis, including PBC and PSC, offering actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

In this issue of Clinics in Liver Disease, guest editor Dr. Sammy Saab brings his considerable expertise to the topic of Hepatic Encephalopathy. Hepatic encephalopathy (HE) is a reversible syndrome in patients with advanced liver dysfunction, and is characterized by a wide spectrum of neuropsychiatric abnormalities resulting from the accumulation of neurotoxic substances in the brain. In this issue, top experts provide detailed clinical reviews devoted to the epidemiology, manifestations, and management of HE in the hopes of improving patient outcomes. - Contains 13 relevant, practice-oriented topics including clinical manifestations of HE; laboratory abnormalities of HE; pharmacologic management of HE; nontraditional treatment of HE; social impact of HE; future therapies of HE; and more. - Provides in-depth clinical reviews on hepatic encephalopathy, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

In this issue of Clinics in Liver Disease, guest editor Dr. Pierre M. Gholam brings his considerable expertise to the topic of Portal Hypertension and Its Complications. Portal hypertension is often one of the major complications seen in advanced liver disease. Patients can be asymptomatic for years and considered compensated. How to manage patients prior to the point of hepatic decompensation is of utmost importance, due to the impact on life expectancy and quality. The timely clinical reviews in this issue will help hepatologists manage these patients and improve outcomes. - Contains 12 relevant, practice-oriented topics including non-invasive assessment of portal hypertension; radiological and surgical treatments of portal hypertension; bleeding complications of portal hypertension; cognitive issues and portal hypertension; surgical considerations in portal hypertension; and more. - Provides in-depth clinical reviews on portal hypertension and its complications, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

Hepatitis B and C cause most cases of hepatitis in the United States and the world. The two diseases account for about a million deaths a year and 78 percent of world's hepatocellular carcinoma and more than half of all fatal cirrhosis. In 2013 viral hepatitis, of which hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most common types, surpassed HIV and AIDS to become the seventh leading cause of death worldwide. The world now has the tools to prevent hepatitis B and cure hepatitis C. Perfect vaccination could eradicate HBV, but it would take two generations at least. In the meantime, there is no cure for the millions of people already infected. Conversely, there is no vaccine for HCV, but new direct-acting antivirals can cure 95 percent of chronic infections, though these drugs are unlikely to reach all chronically-infected people anytime soon. This report, the first of two, examines the feasibility of hepatitis B and C elimination in the United States and identifies critical success factors. The phase two report will outline a strategy for meeting the elimination goals discussed in this report.

Testing and diagnosis of hepatitis B (HBV) and C (HCV) infection is the gateway for access to both prevention and treatment services, and is a crucial component of an effective response to the hepatitis epidemic. Early identification of persons with chronic HBV or HCV infection enables them to receive the necessary care and treatment to prevent or delay progression of liver disease. Testing also provides an opportunity to link people to interventions to reduce transmission, through counselling on risk behaviors and provision of prevention commodities (such as sterile needles and syringes) and hepatitis B vaccination. These are the first WHO guidelines on testing for chronic HBV and HCV infection and complement published guidance by WHO on the prevention, care and treatment of chronic hepatitis C and hepatitis B infection. These guidelines outline the public health approach to strengthening and expanding current testing practices for HBV and HCV, and are intended for use across age groups and populations.

The global epidemic of hepatitis B and C is a serious public health problem. Hepatitis B and C are the major causes of chronic liver disease and liver cancer in the world. In the next 10 years, 150,000 people in the United States will die from liver disease or liver cancer associated with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections. Today, between 800,000 and 1.4 million people in the United States have chronic hepatitis B and between 2.7 and 3.9 million have chronic hepatitis C. People most at risk for hepatitis B and C often are the least likely to have access to medical services. Reducing the rates of illness and death associated with these diseases will require greater awareness and knowledge among health care workers, improved identification of at-risk people, and improved access to medical care. Hepatitis B is a vaccine-preventable disease. Although federal public health officials recommend that all newborns, children, and at-risk adults receive the vaccine, about 46,000 new acute cases of the HBV infection emerge each year, including 1,000 in infants who acquire the infection during birth from their HBV-positive mothers. Unfortunately, there is no vaccine for hepatitis C, which is transmitted by direct exposure to infectious blood. Hepatitis and Liver Cancer identifies missed opportunities related to the prevention and control of HBV and HCV infections. The book presents ways to reduce the numbers of new HBV and HCV infections and the morbidity and mortality related to chronic viral hepatitis. It identifies priorities for research, policy, and action geared toward federal, state, and local public health officials, stakeholder, and advocacy groups and professional organizations.

Many bacteria, viruses, protozoa, and fungi play key roles in the development of gastrointestinal diseases, and this practical reference brings you up to speed with this increasingly important area. Covering a broad range of GI diseases and cancers, this resource provides an expert overview of the field, ideal for all gastroenterologists and infectious disease physicians. - Covers infections associated with gastroesophageal reflux disease and Barrett's esophagus, gallbladder disease, acute pancreatitis, small intestinal bacterial overgrowth, irritable bowel syndrome, inflammatory bowel disease, appendicitis, Whipple Disease, Crohn's Disease, and more. - Discusses esophageal cancer, gastric cancer, cholangiocarcinoma, hepatocellular carcinoma, and colorectal cancer. - Includes chapters on gut microbiome, fecal transplants, and the molecular pathgenesis of gastrointestinal infections. - Consolidates today's available information on this timely topic into a single convenient resource.

Liver Pathophysiology: Therapies and Antioxidants is a complete volume on morphology, physiology, biochemistry, molecular biology and treatment of liver diseases. It uses an integral approach towards the role of free radicals in the pathogenesis of hepatic injury, and how their deleterious effects may be abrogated by the use of antioxidants. Written by the most prominent authors in the field, this book will be of use to basic and clinical scientists and clinicians working in the biological sciences, especially those dedicated to the study and treatment of liver pathologies. Presents the most recent advances in hepatology, with a special focus on the role of oxidative stress in liver injury. Provides in vivo and in vitro models to study human liver pathology. Explains the beneficial effects of antioxidants on liver diseases. Contains the most recent and modern treatments of hepatic pathologies, including, but not limited to, stem cells repopulation, gene therapy and liver transplantation.